Atherosclerosis pathophysiology and the role of novel risk factors: A clinicobiochemical perspective

Angiology

Volumn 58, Issue 5, 2007, Pages 513-522

  Mallika, V ^a   Goswami, Binita ^b   Rajappa, Medha ^c  

^a G B PANT HOSPITAL   (India)

^b MAULANA AZAD MEDICAL COLLEGE   (India)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C; HOMOCYSTEINE; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DISEASE COURSE; DISEASE SEVERITY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEREDITY; HUMAN; HYPERCOAGULABILITY; HYPERLIPIDEMIA; INFLAMMATION; LIFESTYLE MODIFICATION; LIPID METABOLISM; METABOLIC SYNDROME X; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; THROMBOCYTE AGGREGATION; TREATMENT PLANNING;

ATHEROSCLEROSIS; BACTERIAL INFECTIONS; BLOOD COAGULATION; CELL ADHESION MOLECULES; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FREE RADICALS; GENETIC PREDISPOSITION TO DISEASE; HOMOCYSTEINE; HUMANS; INDIA; INFLAMMATION; LEUKOCYTES; LIPOPROTEIN(A); METABOLIC SYNDROME X; OXIDATIVE STRESS; PLATELET AGGREGATION; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 35448982744     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319707303443     Document Type: Review

References (93)

1. Fleming RM: Angina and coronary ischemia are the result of coronary regional blood flow differences. J Amer Coll Angiol 1: 127-42, 2003.
2. Schoen FJ The Heart in Robbin's Pathological Basis of Disease. 5 th ed. New York: W.B. Saunders Co. ; 1994: 517-582.
3. Fleming RM The Pathogenesis of Vascular Disease. Textbook of Angiology. New York: Springer-Verlag ; 1999: 787-798.
4. Braunwald E. Heart Disease. A Textbook of Cardiovascular Disease. Vol 2, 5 th ed. New York: W.B. Saunders Co. ; 1997: 1105-1160.
5. Alexander RW, Schlant RC, Fuster V., O'Rouke RA, Roberts R., Sonnenbuck EH Hurst's. The Heart Arteries and Veins. Vol. 1, 9 th ed. New York: McGraw-Hill ; 1998: 1139-1196.
6. Boon NA, Fox Kaa, Bloomfield P., Bradbuny A. Cardiovascular Disease in Davidson's Principles and Practice of Medicine. 19 th ed. New York: Churchill Livingstone ; 2002 ; 357-782.
7. Fauci AS, Braunwald E., Isselbacher KJ, et al. Harrison's Principles of Internal Medicine. Vol. 1, 15 th ed. New York: McGraw-Hill ; 2003: 1377-1398.
8. Austin MA, King MC, Varnizan KM: Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 82: 495-506, 1990.
9. Lamarche B., St. Pierre AC, Ruel IL A prospective population based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol 17: 859-865, 2001.
10. Blake GJ, Tvos JD, Rifai N. Low density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106: 1930-1937, 2002.
11. Lamarche B., Lemieux I., Despres JP The small dense LDL phenotype and the risk of coronary heart disease: epidemiology pathophysiology and therapeutic aspects. Diabetes Metab 25: 199-211, 1999.
12. Vakkilainen J., Steiner G., Ansauer JC: Relationships between low density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107: 1733-1737, 2003.
13. Holvoet P., Mertens A., Verhamme P. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21: 844-848, 2001.
14. Hulthe J., Iagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study). Arterioscler Thromb Vasc Biol 22: 1162-1167, 2002.
15. Havel RJ Role of triglyceride rich lipoproteins in progression of atherosclerosis. Circulation 81: 694-696, 1990.
16. Krauss RM Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 13B-17B, 1998.
17. Hodis HN, Mack WJ, Azen SP Triglyceride and cholesterol rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 90: 42-49, 1994.
18. Alanpovic P., Mack WJ, Knight-Gibson C. The role of triglyceride rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 17: 715-722, 1997.
19. Sigurdsson G., Baldursdottir A., Sigvaldason H. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 62: 1251-1254, 1992.
20. Walldius G., Jungner I., Holmer I. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358: 2026-2033, 2001.
21. Sacks FM, Alaupovic P., Moye LA: VLDL, apolipoproteins B, C III and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial. Circulation 102: 1886-1892, 2000.
22. Schaefer EJ, McNamara JR, Shan PK: Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 25: 989-994, 2002.
23. Marx N., Sukhova GK, Collins T., Libby P., Plutzky J.: PPAR α activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99: 3125-3131, 1999.
24. Neve BP: PPAR α agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 103: 207-212, 2001.
25. Delerive P.: Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative crosstalk with transcription factors NF-kB and AP-I. J Biol Chem 274: 32048-32054, 1999.
26. Castro Cabezas M, Halkes CJ, Meijjssen S.: Diurnal triglyceride profiles: a novel approach to study triglyceride changes. Atherosclerosis 155: 219-228, 2001.
27. Lewis GF, O'Meara NM, Soltys PA: Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab 72: 934-944, 1991.
28. Patsch JR, Miesenback G., Hopferwieser T.: Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 12: 1336-1345, 1992.
29. Weintraub MS, Grosskopf I., Rassin T.: Clearance of chylomicron remnants in normolipidemic patients with coronary artery disease: Case control study over three years. BMJ 312: 936-939, 1996.
30. Zilversmit DB: Atherogenesis: A postprandial phenomenon. Circulation 60: 473-485, 1979.
31. Loscalzo J.: Lipoprotein (a): a unique risk factor for atherothrombotic disease. Arteriosclerosis 10: 672-679, 1990.
32. Loscalzo J., Weinfeld M., Flees GM, Scanu AM, Fogelman AM: Lipoprotein (a), fibrin binding and plasminogen activation. Arteriosclerosis 10: 240-245, 1990.
33. Lawn RM: Lipoprotein (a) in heart disease. Sci Am 266: 54-60, 1992.
34. Dalen GH, Guyton JR, Mohammad A.: Association of levels of lipoprotein (a), plasma lipids and other lipoproteins with coronary arteries documented by angiography. Circulation 74: 758-765, 1986.
35. Mbewu AD, Duington PN: Lipoprotein (a) structure, properties, and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis 85: 1-14, 1990.
36. Galle J., Bengen J., Schollmeyer P., Wanner C. Impairment of endothelium-dependent diation of rabbit renal arteries by oxidized lipoprotein (a). Circulation 92: 1582-1589, 1995.
37. Rosenson RS: Assessing risk across the spectrum of patients with the metabolic syndrome. Am J Cardiol 96: 8E - 10E, 2005.
38. Sorrentino MJ: Implications of the metabolic syndrome the new epidemic. Am J Cardiol 96: 3E - 7E, 2005.
39. Navab M.: High density lipoprotein associated enzymes: their role in vascular biology. Curr Opin Lipidol 9: 449-456, 1998.
40. Schmidt AM, Yan SD, Wautier JL, Stern D.: Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Cri Res 84: 489-497, 1999.
41. Miller GJ: Hemostasis and cardiovascular risk. The British and European experience. Arch Pathol Lab Med 116: 1318-1321, 1992.
42. Meade TW, Ruddock V., Sterling Y.: Fibrinolytic activity, clotting factors and long term incidence of ischemic heart disease in the Northwick Park Heart Study. Lancet 342: 1076, 1993.
43. Erdste E.: Plasma fibrinogen an independent cardiovascular risk factor. J Intern Med 227: 365-372, 1990.
44. Juhan-Vague I., Allesi MC: Plasminogen activator inhibitor and atherothrombosis. Thromb Haemost 70: 138-143, 1993.
45. Fleming RM Using C-reactive protein as a marker of bacterially aggravated atherosclerosis in acute coronary syndromes. J Amer Coll Angiol 2003 ; 1: 165-171, 2003.
46. Fuster V., Fayad ZA, Badimon JJ: Acute coronary syndromes: biology. Lancet 353: S115 - S119, 1999.
47. Saksela O., Rifkin DB: Cell-associated plasminogen activation/regulation and physiological functions. Annu Rev Cell Biol 4: 93-126, 1988.
48. Libby P.: Inflammation in atherosclerosis. Nature 420: 868-874, 2002.
49. Drexler H.: Factors involved in the maintenance of endothelial function. Am J Cardiol 82: 35-45, 1998.
50. Ross R.: Atherosclerosis. An inflammatory disease. N Engl J Med 340: 115-126, 1999.
51. Davignon J., Ganz P.: Role of endothelial dysfunction in atherosclerosis. Circulation 109 (III):III-27-III-32, 2002.
52. Harrison D., Griending KK, Landmesser U.: Role of oxidative stress in atherosclerosis. Am J Cardiol 91: 7A - 11A, 2003.
53. O'Donnell VB: Free radicals and lipid signaling in endothelial cells. Antioxid Redox Signal 5: 195-203, 2003.
54. Li D., Yang B., Mehta JL: Ox-LDL induces apoptosis in human coronary artery endothelial cells: role of PKC, PTK, Bcl2, and Fas. Am J Physiol 275: H568 - H576, 1998.
55. Inoue M., Itoh H., Tanaka T. Oxidised LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator activator receptor gamma. Arterioscler Thromb Vasc Biol 21: 560-566, 2001.
56. Auge N., Garcia V., Maupas-Schwalm F.: Oxidized LDL induced smooth muscle cell proliferation involves the EGF receptor/PI-3 Kinase/Akt and the sphingolipid signaling pathways. Arterioscler Thromb Vasc Biol 22: 1990-1995, 2002.
57. Li D., Liu L., Chen H., Sawamura T., Ranganathan S., Mehta JL: Lox-I mediates OX-LDL induced expression of matrix metalloproteinase in human coronary artery endothelial cells. Circulation 107: 612-617, 2003.
58. Li D., Liu L., Chen H., Sawamura T., Mehta JL: Lox-1, an oxidized LDL endothelial receptor, induces CD40/ CD40L signaling in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol 23: 816-821, 2003.
59. Libby P., Ridker PM, Maseri A.: Inflammation and atherosclerosis. Circulation 105: 1135-1143, 2002.
60. Shah PK: Plaque disruption and thrombosis: potential role of inflammation and infection. Cardiol Clin 17: 271-281, 1999.
61. Ross R.: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809, 1993.
62. Cheng Jwn, Rivera NG: Infection and atherosclerosis- focus on cytomegalovirus and chlamydia pneumoniae. Ann Pharmacother 32: 1310-1316, 1998.
63. Mehta JL, Saldeen Tgp, Rand K.: Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary disease. J Am Coll Cardiol 31: 1217-1225, 1998.
64. Kalayoglu MV, Libby P., Byrne GI: Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 288: 2724-2731, 2002.
65. Fabricant CG, Fabricant J., Litrenta MM: Virus induced atherosclerosis. J Exp Med 148: 335-340, 1978.
66. Gerrity RG: The role of the monocyte in atherogenesis. Transition of blood borne monocytes into foam cells in fatty lesions. Am J Pathol 103: 181-190, 1981.
67. Plutzky J.: Inflammatory pathways in atherosclerosis and acute coronary syndrome. Am J Cardiol 88: 10K - 15K, 2001.
68. Pober JS, Cotxao RS: Cytokines and endothelial cell biology. Physiol Rev 70: 427-451, 1990.
69. Mehta JL, Nichols WW, Mehta P.: Neutrophils as potential participants in acute myocardial ischemia. J Am Coll Cardiol 11: 1309-1316, 1988.
70. Hansson GK, Jonasson L., Seifert PS, Stemme S.: Immune mechanisms in atherosclerosis. Arteriosclerosis 9: 567-578, 1989.
71. Cybulsky MI, Gimbrone MA: Endothelial expression of a mononuclear leucocyte adhesion molecule during atherogenesis. Science 251: 788-791, 1991.
72. Li H., Cybulsky MI, Gimbrone MA, Libby P.: An atherogenic diet rapidly induces VCAM-1, a cytokine mononuclear leukocyte adhesion molecule, in rabbit endothelium. Arterioscler Thromb 13: 197-204, 1993.
73. Johnson RC Absence of P-selectins delays fatty streak formation in mice. J Clin Invest 99: 1037-1043, 1997.
74. Dong ZM: The combined role of P-and E-selectins in atherosclerosis. J Clin Invest 102: 145-152, 1998.
75. Collins T., Cybulsky MI: NF-KB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 107: 255-264, 2001.
76. Boisvert WA, Santiago R., Curtiss LK, Terkeltaub RA: A leucocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor deficient mice. J Clin Invest 101: 353-363, 1998.
77. Mach F.: Differential expression of three T-lymphocyte activating CXC chemokines by human atheroma associated cells. J Clin Invest 104: 1041-1050, 1999.
78. Haley KJ: Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway. Circulation 102: 2185-2189, 2000.
79. Rajavashisth TB: Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1 matrix metalloproteinase. J Biol Chem 274: 11924-11929, 1999.
80. Fleming RM: The effect of high, moderate and low fat diets on weight loss and cardiovascular disease risk factors. Preventive Cardiol 5: 110-118, 2002.
81. Fleming RM: The influence of diet on homocysteine. Fourth International Homocysteine Conference ; Basel, Switzerland, June 2003.
82. Wilcken Del, Wilcken B.: The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 57: 1079-1082, 1976.
83. Harpel PC, Chang VT, Borth W.: Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin. A potential biochemical link between thrombosis, atherogenesis and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 89: 10193-10197, 1992.
84. Lentz SR, Sadler JE: Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 88: 1096-1914, 1991.
85. Nishinaga M., Ozawa T., Shimado K.: Homocysteine, a thrombogenic agent, suppresses anticoagulant heparin sulphate expression in cultured porcine aortic endothelial cells. J Clin Invest 92: 1381-1386, 1993.
86. Haynes WG: Hyperhomocysteinemia. Vascular functions and atherosclerosis: effect of vitamins. Cardiovasc Drugs Ther 16: 391-399, 2002.
87. Wall R., Harlan JM, Harker LA, Striker GE: Homocysteine induced endothelial cell injury in vivo: a review. Thromb Res 18: 113-121, 1980.
88. Dudman Npb, Temple SE, Guo XW, Fu WY, Perry MA: Homocysteine enhances neutrophil endothelial interactions in vivo. Cir Res 84: 409-416, 1999.
89. Heinecke JW, Rosen H., Suzuki LA, Chait A.: The role of sulphur containing amino acids in super oxide production and modification of low density lipoprotein in arterial smooth muscle cells. J Biol Chem 262: 10098-10103, 1987.
90. Upchurch GR, Welch GN, Fabian AJ: Homocysteine decreases bioavailable Nitric Oxide by a mechanism involving glutathione peroxidase. J Biol Chem 272: 17012-17017, 1997.
91. Hiltunen MO, via-Herttual S: DNA methylation, smooth muscle cells and atherogenesis. Arterioscler Thromb Vasc Biol 20: 1557-1564, 2000.
92. Krumkan II, Culmsee C., Chan SL,, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxins. J Neurosci 20: 6920-6926, 2000.
93. Toyota Y., Yamamura T., Miyake Y., Yamamoto A.: Low density lipoprotein (LDL) binding affinity for the LDL receptor in hyperlipoproteinemia. Atherosclerosis 147: 77-86, 1999.